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Abstract
The association between several cancers and selenium
status has been investigated in epidemiological studies.
However, few results concerning bladder cancer have
been reported thus far. The association between toenail
selenium status and subsequent bladder cancer incidence
was investigated in a prospective cohort study among
120,852 men and women aged 55–69 years at baseline
(September 1986). The cohort members completed a
questionnaire on risk factors for cancer and provided
toenail clippings for determination of baseline selenium
status. Follow-up for incident cancer was established by
record linkage to cancer registries until December 1992.
The multivariable case-cohort analysis was based on 431
bladder cancer cases and 2,459 subcohort members, for
whom toenail selenium levels were available. The age-,
sex- and smoking-adjusted rate ratios (95% confidence
intervals) for increasing quintiles of toenail selenium were
1.00 (reference), 1.09 (0.80–1.48), 0.55 (0.38–0.79), 0.63
(0.43–0.91), and 0.67 (0.46–0.97), respectively (P-trend <
0.01). Analyses with selenium as a continuous variable
supported these findings. An inverse association between
toenail selenium and bladder cancer risk was most
pronounced among ex-smokers (P-trend < 0.01); was
similar for subjects with high versus low intakes of -
carotene, vitamin C, and vitamin E; and was mainly
confined to invasive transitional cell carcinomas of the
urinary bladder, irrespective of tumor morphology. We
conclude that the evidence is in favor of an inverse
association between selenium and bladder cancer risk.
Introduction
Bladder cancer is the most common cancer of the urinary tract
and is the seventh most common cancer among men, account-
ing for approximately 200,000 new cases per year worldwide
(1). Over the last four decades, many epidemiological studies
and several reviews have been conducted to investigate deter-
minants of bladder cancer (2–6). These studies suggested that
bladder cancer is influenced by environmental factors, includ-
ing cigarette smoking, fluid consumption, schistosomal infec-
tions, exposure to industrial chemicals (e.g., aromatic amines),
and diet.
It has been suggested that selenium may protect against
cancer, particularly because of its antioxidant properties, al-
though other mechanisms have also been proposed (7–9). Se-
lenium is an essential trace element required for normal func-
tion, growth, and reproduction (10, 11). Several animal,
ecological, and epidemiological studies support the hypothesis
that low intake of selenium is associated with an increased risk
of cancer (8). However, only five epidemiological studies have
concentrated on urinary bladder cancer incidence (7–9, 12, 13).
Most of these studies assessed short-term selenium intake in
serum and were based on small numbers of cases.
In the present study, we were able to explore the relation-
ship of prediagnostic toenail selenium to human bladder cancer
prospectively with substantially more cases than in previous
studies.
Materials and Methods
Cohort. The Netherlands Cohort Study is a population-based
prospective study on diet and cancer started in the Netherlands
in September 1986. The cohort includes 58,279 men and 62,573
women aged 55–69 years at the start of the study. The study
population originated from 204 municipal population registries
throughout the country. The case cohort approach was used for
data processing and analysis (14). Cases were enumerated from
the entire cohort, whereas the accumulated person years in the
cohort were estimated from a subcohort sample. Following this
approach, a subcohort of 3,500 subjects (1,688 men and 1,812
women) was randomly sampled from the cohort after the base-
line exposure measurement. The subcohort has been followed
up for vital status information. No subcohort members were lost
to follow-up, during the follow-up period. The study design,
including data collection strategies, has been described in detail
previously (15).
Follow-Up. Follow-up for incident cancer was established by
record linkage to cancer registries and the Dutch national da-
tabase of pathology reports (16). The completeness of cancer
follow-up was estimated to be over 96% (17). The present
analysis is restricted to cancer incidence in 6.3 years of follow-
up, from September 1986 to December 1992, because only
information of toenail selenium status for cases diagnosed until
1992 were available at the time of the analysis. After excluding
prevalent cases with cancer other than skin cancer, a total of
3,346 subcohort members (1,630 men and 1,716 women) and
619 incident cases (532 men and 87 women) with microscop-
ically confirmed, incident carcinomas of the urinary bladder,
ureters, renal pelvis, or urethra were identified. Of these cases,
584 (94.3%) were diagnosed with bladder cancer, of which 559
(95.7%) were transitional cell carcinomas. Because the over-
whelming majority of tumors occurred in the urinary bladder
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and the ureters, renal pelvis, and urethra are covered by the
same urothelium as the urinary bladder, the term bladder cancer
is used as a synonym for these neoplasms.
Exposure Status. At baseline, all cohort members completed
a self-administered questionnaire on risk factors for cancer and
potential confounding variables. The questionnaire data were
key entered twice and processed in a standardized manner,
blinded with respect to case/subcohort status to minimize ob-
server bias in coding and interpretation of the data. Toenail
clippings had been provided by 438 patients with bladder
cancer (76.8%) and by 2569 (70.8%) subcohort members.
In 1992, the toenail selenium analyses for subcohort mem-
bers were carried out by the Interfaculty Reactor Institute at
Delft University (Delft, the Netherlands), using instrumental
neutron activation analysis. This method, using the SBP facil-
ity, and evaluation of accuracy and precision have been de-
scribed elsewhere (18).
In 1996, toenail selenium levels of bladder cancer cases
were determined with the CAFIA, also carried out by the
Interfaculty Reactor Institute (19). The selenium determina-
tion for the cases was also based on the measurement of the
induced radioactivity of the short-lived 77mSe radionuclide
(half-life, 17.5 s), but cyclic activation and measurement was
applied to achieve the required sensitivity (20). Each sample
passed 6 successive cycles of 17-s irradiation at a thermal
neutron flux of 3.7.1016 m-2s-1, 3 s decay, and 17 s counting
at 1 cm from a 40% Ge detector. The results of the six
countings were added. The accuracy of the instrumental
neutron activation analysis was checked by analysis of a
certified bovine liver standard (Standard Reference Material
1577b of the United States National Institute of Standards
and Technology). For 30 determinations, a mean value  SD
of 0.74  0.04 g/g selenium (N  49) was observed against
a certified value of 0.73  0.06 g/g.
Because of problems with the detection of selenium in
samples weighing less than 10 mg and sometimes in samples
with very high calcium contents, 7 and 110 specimens were
excluded from the bladder cancer and subcohort groups, re-
spectively. Together with the case group, the toenail selenium
levels for 40 subcohort members were assessed with the CAFIA
facility in addition to original assessment with the SBP facility
to evaluate comparability. The mean selenium level  SD
using the SBP facility (0.551  0.04 g/g) was comparable to
mean selenium levels using the CAFIA facility (0.552  0.05
g/g) for these subjects. The Pearson correlation coefficient
between toenail selenium levels assessed by the CAFIA facility
and those estimated by the SBP facility was 0.95 (P  0.01).
Toenail selenium data were available for analysis from 431
bladder cancer cases (372 men and 59 women) and 2459
subcohort members (1211 men and 1248 women).
Statistical Analyses. To evaluate the potential influence of
prediagnostic cancer on toenail selenium levels, we categorized
the cases according to the year of follow-up in which the
diagnosis was made. Mean toenail selenium levels of bladder
cancer cases were compared according to year of follow-up.
Toenail selenium levels were categorized into quintiles accord-
ing to the distribution in the subcohort. Incidence RRs3 and
corresponding 95% CIs for bladder cancer were estimated using
exponentially distributed failure time regression models (21)
with the Stata statistical software package (22). Standard errors
were estimated using the robust Hubert-White sandwich esti-
mator to account for additional variance introduced by sam-
pling from the cohort. This method is equivalent to the vari-
ance-covariance estimator presented by Barlow (23) and Lin
and Ying (24). Because of skewedness to the right, continuous
data on toenail selenium concentrations were normalized with
a loge transformation. The RR was calculated per standard unit
(z-score) of toenail selenium levels. This is comparable to an
increment of 0.202 g/g selenium. We confirmed constancy of
the baseline hazard visually by plotting the natural logarithm of
the baseline survival function against failure time.
The following variables were considered as potential con-
founders: intake of alcohol (g/day), coffee (ml/day), tea (ml/
day), water (ml/day), vegetables (g/day), and fruit (g/day);
current cigarette smoking (yes/no); smoking amount (ciga-
rettes/day); smoking duration (years of cigarette smoking);
occupational exposure to dye, rubber, leather, or vehicle fumes
(ever/never); and first-degree family history of bladder cancer
(yes/no). Those variables that showed a more than 10% influ-
ence on the risk of bladder cancer when considered in a mul-
tivariable model were included as covariates in multivariable
analyses. If one or more dietary covariates were incorporated in
the regression model, subjects with incomplete or inconsistent
dietary data were excluded, according to criteria described
previously (25). Subgroup analyses conditional on cigarette
smoking status (never/ex/current) and years since smoking ces-
sation were performed to evaluate interaction of selenium by
smoking. Because earlier studies (13, 26, 27) suggested a po-
tential interaction between vitamin levels and selenium, we
stratified the results by high versus low -carotene, vitamin C,
and vitamin E intake status of the subjects. Low and high are
defined as the two lowest quintiles and the two highest quintiles
of intake, respectively. Furthermore, subgroup analyses were
conducted after stratification by morphology and invasiveness
of bladder cancer. Because the RRs concerning toenail sele-
nium level and bladder cancer risk were similar for men and
women, the results are presented for men and women com-
bined.
Results
Table 1 displays the average toenail selenium levels among
bladder cancer cases according to sex and year of follow-up.
Those of the subcohort are presented in a footnote of the table.
Female cases appeared to have higher toenail selenium levels
than male cases (P  0.02). The mean toenail selenium level
for the cases (men, 0.536 g/g; women, 0.568 g/g) was lower
than that for the subcohort members (men, 0.547 g/g; women,
0.575 g/g). Cases diagnosed in the first years of follow-up had
lower toenail selenium levels than cases diagnosed later after
adjustment for sex (Table 1).
Toenail selenium was inversely associated with bladder
cancer risk in men and women combined (Table 2). The age-
and sex-adjusted RR was 0.54 (95% CI, 0.38–0.76) comparing
highest to lowest quintiles of toenail selenium. After adjustment
for age, sex, number of cigarettes smoked per day, and years of
cigarette smoking, the RR was 0.67 (95% CI 0.46–0.97) com-
paring the same quintiles of toenail selenium (P-trend  0.01).
This reduced bladder cancer incidence appears to be limited to
the highest three quintiles of the toenail selenium distribution.
The RR decreased by 7% for each increment of 1 standard unit
of toenail selenium (0.202 g/g). After exclusion of those
patients whose cancer was diagnosed during their first year of
follow-up, the negative association between toenail selenium
3 The abbreviations used are: RR, rate ratio; CI, confidence interval; SBP,
Snelle Buizenpost; CAFIA, Carbonfiber Autonomous Facility for Irradiation
and Analysis.
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level and bladder cancer risk persisted (Table 2). Additional
correction for current cigarette smoking, coffee, tea, water,
vegetables, fruit, occupational exposure, and family history of
bladder cancer did not change the risk substantially (data not
shown).
We did not find statistically significant interactions re-
garding bladder cancer risk between toenail selenium and cig-
arette smoking status (P  0.19), amount (P  0.76), or
duration (P  0.61). However, an inverse association between
toenail selenium and bladder cancer risk was limited to ex-
smokers (P-trend  0.01), and no inverse association was
found among never and current smokers (Table 3). The corre-
lation between toenail selenium status and years of smoking
cessation was 0.08 (P  0.01). Among ex-smokers, the asso-
ciation between toenail selenium and bladder cancer risk was
comparable for those who have refrained from smoking for
10 years and those who have refrained from smoking for10
years (Table 3).
To evaluate effect modification of the association between
toenail selenium and bladder cancer risk by the intake level of
antioxidant vitamins -carotene, vitamin C, and vitamin E, we
also evaluated whether the association with bladder cancer
depended on intake of these antioxidants (Table 4). The inverse
association between toenail selenium and bladder cancer risk
persisted for subjects with different intakes of -carotene, vi-
tamin C, and vitamin E (Table 4). We found no statistically
Table 1 Toenail selenium levels (g/g) in bladder cancer cases according to sex and time between baseline and bladder cancer diagnosis; Netherlands Cohort Study
(1986–1992)
Casesa No. of
subjects
Toenail selenium level (g/g)
Mean SD Pb
Sex
Men 372 0.536 0.215 Reference
Women 59 0.568 0.122 0.02
Year of follow-upc
1 47 0.518 0.091 0.04
2 61 0.523 0.263 0.21
3 74 0.546 0.128 0.50
4 75 0.544 0.155 0.90
5 70 0.568 0.154 0.63
6 84 0.590 0.721 Reference
7 20 0.595 0.123 Reference
a Mean  SD selenium levels in subcohort members were 0.547  0.126 g/g for men (n  1211) and 0.575  0.109 g/g for women (n  1248).
b Partial t tests between strata and reference group, based on In-transformed toenail selenium levels.
c Presented results per year of follow-up were adjusted for sex through linear regression analysis.
Table 2 Incidence RR of bladder cancer according to toenail selenium levels; Netherlands Cohort Study (1986–1992)
Quintiles of toenail selenium
(boundaries in g/g)
All years of follow-up First year
excluded
Cases in
cohort
Person years
in subcohort RR (95% CI)
a RR (95% CI)b RR (95% CI)b
1 (0.483) 114 2986 1.00 (reference) 1.00 (reference) 1.00 (reference)
2 (0.483 to 0.530) 116 3022 1.05 (0.79–1.40) 1.09 (0.80–1.48) 1.19 (0.86–1.64)
3 (0.530 to 0.573) 78 3031 0.51 (0.36–0.73) 0.55 (0.38–0.79) 0.61 (0.42–0.89)
4 (0.573 to 0.630) 62 2993 0.53 (0.37–0.76) 0.63 (0.43–0.91) 0.63 (0.42–0.94)
5 (0.630) 61 3001 0.54 (0.38–0.76) 0.67 (0.46–0.97) 0.78 (0.54–1.14)
P for linear trend 0.01 0.01 0.01
Increment in standard unitsc 0.86 (0.77–0.96) 0.94 (0.83–1.05) 0.89 (0.79–1.00)
a Adjusted for age (years) and sex.
b Adjusted for age, sex, number of cigarettes/day, and years of cigarette smoking.
c z-scores based on In-transformed toenail selenium levels (increment of 0.202 g/g).
Table 3 Incidence RR of bladder cancer according to toenail selenium levels and smoking status; Netherlands Cohort Study (1986–1992)
Smoking status and cessationa No. of
cases
Quintile of toenail selenium (boundaries in g/g)
P trend
1 (0.483) 2 (0.530) 3 (0.573) 4 (0.630) 5 (0.630)
Neverb 51 1.00 (reference) 2.69 (1.02–7.09) 1.37 (0.50–3.79) 1.09 (0.38–3.14) 1.36 (0.50–3.69) 0.62
Exc 186 1.00 (reference) 0.74 (0.46–1.19) 0.48 (0.28–0.81) 0.49 (0.29–0.83) 0.44 (0.26–0.75) 0.01
10 yrs 89 1.00 (reference) 0.42 (0.19–0.94) 0.47 (0.21–1.08) 0.45 (0.20–1.01) 0.30 (0.12–0.75) 0.01
10 yrs 96 1.00 (reference) 1.06 (0.55–2.06) 0.48 (0.22–1.01) 0.47 (0.20–1.09) 0.58 (0.29–1.18) 0.01
Currentc 170 1.00 (reference) 1.36 (0.86–2.14) 0.45 (0.24–0.86) 0.76 (0.39–1.47) 1.13 (0.56–2.27) 0.25
a P for interaction was 0.19.
b Adjusted for age (years) and sex.
c Adjusted for age (years), sex, number of cigarettes/day, and years of cigarette smoking.
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significant interaction effect between these antioxidants and
toenail selenium (P  0.58, 0.16, and 0.96, respectively).
An inverse association between toenail selenium level and
bladder cancer risk was most pronounced in invasive transi-
tional cell carcinomas of the urinary bladder, irrespective of
tumor morphology (P-trend  0.01 and  0.01 for invasive
papillary and non-papillary tumors, respectively; Table 5). The
RRs for noninvasive tumors did not indicate a clear inverse
association for toenail selenium (Table 5).
Discussion
These data showed a small inverse association between baseline
toenail selenium and subsequent bladder cancer risk. The as-
sociation was most pronounced in ex-smokers and was mainly
confined to invasive carcinomas of the bladder. The association
appeared to be independent of -carotene, vitamin C, and
vitamin E intake.
Preclinical symptoms of bladder cancer might influence
selenium status. However, one advantage of this and other
prospective studies is that selenium status was assessed before
diagnosis of bladder cancer. In the present study, cases diag-
nosed in the first years of follow-up had lower toenail selenium
levels than cases diagnosed later. This indicates that preclinical
disease may have had influence on selenium status in the first
year of follow-up, although it might also be that lower selenium
status in fact causes bladder cancer to happen sooner. We found
a strong inverse association between continuous selenium ex-
posure and first year bladder cancer incidence (RR, 0.18; 95%
CI, 0.06–0.51). After exclusion of cases diagnosed in the first
year of follow-up, however, the diluted results were similar to
results based on all cases (Table 2). Selection bias is not likely
because the follow-up for cancer incidence and person years
was almost complete (17, 28). Nondifferential information bias
might be prevalent because different selenium assays were used
to assess selenium concentration in toenails. However, both
CAFIA and SBP methods appeared to be highly comparable to
the gold standard (bovine liver), and their correlation was very
high (r  0.95). We therefore expect that the small difference
between both methods will not systematically bias the results.
The large number of bladder cancer cases in this study was
another important advantage.
Diet assessment methods are inadequate to assess sele-
nium intake because selenium content of an individual food can
vary widely due to geographic variation in soil selenium con-
tent. Therefore, previous epidemiological studies on the rela-
tion between selenium and bladder cancer have often relied on
biological markers of selenium status, such as serum selenium
(7, 8, 13) or toenail selenium (12). A selenium marker should
preferably reflect long-term selenium intake. For this reason,
we used levels of selenium in toenails to assess selenium intake
instead of serum selenium, a short-term marker of selenium
intake (18). Available evidence suggests that selenium levels in
Table 4 Incidence RRa of bladder cancer according to toenail selenium levels by category of vitamin intake; Netherlands Cohort Study (1986–1992)
Group No. of
cases
Quintile of toenail selenium (boundaries in g/g)
P-trend
1 (0.483) 2 (0.530) 3 (0.573) 4 (0.630) 5 (0.630)
-Carotene intakeb
Low 167 1.00 (reference) 0.98 (0.59–1.62) 0.50 (0.28–0.89) 0.71 (0.40–1.26) 0.65 (0.36–1.16) 0.02
High 155 1.00 (reference) 1.08 (0.65–1.80) 0.97 (0.55–1.71) 0.66 (0.34–1.26) 0.74 (0.41–1.34) 0.09
Vitamin C intakeb
Low 181 1.00 (reference) 0.95 (0.59–1.53) 0.45 (0.26–0.78) 0.72 (0.41–1.26) 0.77 (0.43–1.37) 0.05
High 140 1.00 (reference) 1.09 (0.64–1.85) 1.01 (0.57–1.80) 0.50 (0.25–1.00) 0.75 (0.41–1.37) 0.06
Vitamin E intakeb
Low 145 1.00 (reference) 1.37 (0.81–2.33) 0.58 (0.30–1.09) 0.76 (0.41–1.42) 0.82 (0.45–1.50) 0.07
High 170 1.00 (reference) 1.09 (0.68–1.75) 0.59 (0.34–1.03) 0.70 (0.38–1.28) 0.73 (0.41–1.29) 0.04
a Adjusted for age (years), sex, number of cigarettes/day, and years of cigarette smoking.
b Low and high are defined as the two lowest quintiles and the two highest quintiles of intake, respectively. For -carotene, the cutoff values for low and high were: 2.36,
2.97 mg/day; for vitamin C the corresponding values were 86.60 and 107.71 mg/day, and for vitamin E the corresponding values were 10.72 and 13.89 mg/day.
The Ps for interaction were 0.58, 0.16, and 0.96 for -carotene, vitamin C, and vitamin E.
Table 5 Incidence RRs for transitional cell carcinoma of the urinary bladder according to toenail selenium levels, with respect to tumor invasiveness and
morphology; Netherlands Cohort Study 1986–1992
Quintiles of toenail selenium
(boundaries in g/g)
Noninvasive (TIS/Ta/T1) Invasive (T2–4)
Non-papillarya
(n  16)
Papillaryb
(n  180)
Non-papillarya
(n  81)
Papillaryb
(n  108)
RR (95% CI)c RR (95% CI)c RR (95% CI)c RR (95% CI)c
1 (0.483) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
2 (0.483 to 0.530) 1.24 (0.31–4.88) 1.23 (0.80–1.88) 1.11 (0.63–1.95) 0.96 (0.58–1.59)
3 (0.530 to 0.573) 1.07 (0.25–4.58) 0.63 (0.37–1.05) 0.45 (0.21–0.96) 0.44 (0.23–0.84)
4 (0.573 to 0.630) 1.28 (0.26–6.42) 0.78 (0.46–1.31) 0.17 (0.05–0.57) 0.64 (0.34–1.20)
5 (0.6300) 0.83 (0.13–5.20) 0.91 (0.55–1.50) 0.62 (0.30–1.28) 0.36 (0.17–0.75)
P for linear trend 0.92 0.18 0.01 0.01
Increment in standard unitsd 1.08 (0.74–1.58) 1.06 (0.87–1.29) 0.84 (0.69–1.02) 0.82 (0.72–0.94)
a ICD-O:M8120.
b ICDO:M8130.
c Adjusted for age, sex, number of cigarettes smoked/day, and years of cigarette smoking.
d z-scores based on In-transformed toenail selenium levels (increment of 0.202 g/g).
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toenails reflect intake integrated for the previous 12 months or
longer (12).
We were not able to explain our results on the basis of
confounding because our results were essentially unchanged
after incorporating into the analyses many known or sus-
pected risk factors for bladder cancer, including current
cigarette smoking; total consumption of alcohol, water, veg-
etables and fruit; high risk occupation; and positive family
history of bladder cancer (data not shown). We made an
attempt to model cigarette smoking habits such that they best
explained bladder cancer. This resulted in a model including
number of years smoked and habitual number of cigarettes
smoked per day, both as continuous variables. When we
added the smoking variables to an age- and sex-adjusted
model, the RR estimates changed only slightly. We therefore
believe that associations observed were not entirely due to
residual confounding by smoking, although we cannot ex-
clude some influence. It should be considered that we could
not completely eliminate confounding bias because the in-
verse association found between low selenium levels and
risk of bladder cancer may also indicate the protective effect
of another nutrient in selenium-rich foods (26).
Recently, Cohen (29) suggested that transitional cell car-
cinoma of the urinary bladder might represent two distinct
diseases: papillary transitional cell carcinoma, which is usually
noninvasive, and the non-papillary type, which tends to be
invasive. In addition to different prognostic and pathogenic
properties, these two diseases appear to involve different mo-
lecular events (29). From an etiological point of view, some
distinction might be important. An inverse association between
toenail selenium level and bladder cancer risk was most pro-
nounced in invasive transitional cell carcinomas of the urinary
bladder, irrespective of tumor morphology. Further research is
needed to evaluate this matter.
The association between total cancer incidence and sele-
nium levels has been investigated in several prospective epi-
demiological studies. However, few results concerning urinary
bladder cancer per se have been reported thus far (Refs. 7, 8,
12, and 13; Table 6). Although the number of bladder cancer
cases in these studies was small, and the mean selenium levels
differed substantially between the studies, most studies, as in
the present study, demonstrated an inverse association between
selenium concentrations and the risk of bladder cancer. Nomura
et al. (13) reported a decrease in relative risk of bladder cancer
for subjects in the highest quintile compared with the lowest
quintile of serum selenium (RR  0.32), although no statisti-
cally significant trend was found (P  0.12). Helzlsouer et al.
(7) similarly reported a decreased bladder cancer risk with
increasing serum levels (P 0.03). When examined by tertiles,
the relative risk associated with the highest tertile of selenium
compared with the lowest tertile was 0.49. A Finnish study (8)
demonstrated a protective effect of selenium for men (RR 
0.34) but not for women (RR  2.51) comparing the four
highest quintiles against the lowest quintile of serum selenium,
although the latter is based on only nine bladder cancer cases.
Of interest in this connection is the fact that serum selenium
levels in this Finnish study were approximately one-half of
those found in the United States. Only one prospective study
investigated the association between toenail selenium levels
and female urinary tract cancer (12). This study did not find an
association between toenail selenium and bladder cancer risk
(P  0.58; Ref. 12; Table 6).
Recently, Clark et al. (9) conducted a randomized, placebo-
controlled cancer prevention trial in low-selenium areas of the
United States to investigate whether selenium supplementation
would decrease cancer incidence. The investigators demon-
strated that, compared with controls, subjects treated with se-
lenium had significant reductions in total cancer mortality (RR,
0.50; 95% CI, 0.31–0.80) and total cancer incidence (RR, 0.63;
95% CI, 0.47–0.85). For bladder cancer, the actual number of
cases was too small to perform statistically meaningful analyses
(9). Although promising, further human experimental research
is needed to evaluate this matter.
The causal interpretation of an inverse association be-
tween selenium and cancer risk is supported by several animal
experiments demonstrating anticarcinogenic effects of sele-
nium, although bladder carcinogenesis has not often been in-
vestigated (30). Several hypotheses have been proposed to
explain the inhibition of tumorigenesis by selenium, including
alterations in carcinogen metabolism, effects on the endocrine
and immune systems, production of cytotoxic selenium metab-
olites, inhibition of protein synthesis, inhibition of specific
enzymes, inhibition of tumor growth, stimulation of apoptosis,
and protection against oxidative stress involving the function of
selenium as a constituent in the antioxidant enzyme glutathione
peroxidase (7, 9–12, 26, 31, 32). The latter mechanism has
received the most attention. The lack of effect of selenium
status among nonsmokers is consistent with this hypothesis
because never smokers have not been exposed to smoking-
induced oxidative stress (33), although lack of effect among
current smokers is not. It might be that the cumulative and
continuing exposure to tobacco smoke among current smokers
may overwhelm the effect of selenium. However, these differ-
ences might also be attributable the chance because no statis-
tically significant effect modification was found.
We found evidence for a small inverse association be-
tween toenail selenium and bladder cancer risk. The decreased
cancer incidence seems largely limited to the highest three
quintiles of the toenail selenium distribution. The association
was most pronounced in ex-smokers and was mainly confined
to invasive carcinomas of the bladder. It appeared to be inde-
pendent of -carotene, vitamin C, and vitamin E intake.
Table 6 Prospective studies of selenium in relation to urinary tract cancer incidence
Study Country Sex Cases Mean selenium level(cases/controls) Exposure Comparison Site RR (95% CI)
Nomura et al., 1987 (13) US Men 29 12.11/12.49 g/dl Serum Highest vs. lowest quintile Bladder 0.32
Helzlsouer et al., 1989 (7) US Both 35 11.1/11.7 g/dl Serum Highest vs. lowest tertile Bladder 0.49 (0.16–1.49)
Knekt et al., 1990 (8) Finland Men 26 6.16/6.53 g/dl Serum Four higher vs. lowest quintile Urinary tract 0.34 (0.06–2.06)
Knekt et al., 1990 (8) Finland Women 9 7.64/6.67 g/dl Serum Four higher vs. lowest quintile Urinary tract 2.51 (0.13–47.9)
Garland et al., 1995 (12) US Women 28 0.826/0.812 g/g Toenail Mean differences Urinary tract P  0.58a
Present study Netherlands Both 431 0.540/0.561 g/g Toenail Highest vs. lowest quintile Urinary tract 0.67 (0.46–0.97)
a P for mean difference between cases and controls.
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